The Association of the British Pharmaceutical Industry (ABPI) has responded to today’s triggering of Article 50 of the Lisbon Treaty by Prime Minister Theresa May, officially starting the process of the United Kingdom (UK) negotiating its departure from the European Union (EU).
With the UK's EU membership providing much of the scientific, regulatory and trade infrastructure for the sector,
the UK EU Life Sciences Transition Programme was established by the Government's Office for Life Sciences in July 2016 to ensure that the sector was in as strong a position as possible as the UK establishes a new relationship with Europe and the rest of the world.
The work of the Programme and its Steering Group to date has been to establish consensus on the issues influencing the maintenance and growth of a world-leading Life Sciences environment in the UK post-Brexit.
Key issues include:
Mike Thompson, Chief Executive of the ABPI said:
"We're pleased with the pragmatic approach taken by Government in preparing for Brexit negotiations.
This has resulted in us making good progress in a number of complex areas including proposals for barrier free trade and the future of medicines regulation.
We will now seek to secure the best possible deal for bringing innovative medicines to patients and protecting the future of the UK's world-leading pharmaceutical industry".
## ENDS ##
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone during work hours (9am to 5pm Monday to Friday):+44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends):+44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.